Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received ...

Sage Therapeutics Inc and Biogen's experimental drug improved symptoms of postpartum depression after 15 days in a late-stage study, the companies said on Wednesday. Skip to main content.

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug ...

Biogen and Sage will shut down the ongoing study of SAGE-324. On today's stock market, Sage stock collapsed 20.6% to 10.38. Biogen stock gained a fraction, closing at 226.03.

Sage Therapeutics, Inc. and Biogen Inc. announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 as a potential treatment in essential tremor.

Sage Therapeutics has priced the oral postpartum depression (PPD) pill it developed with partner Biogen at $15,900 for a full 14-day course of treatment, the company said on Tuesday, months after ...

Sage Therapeutics, Inc. and Biogen Inc. today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor.

For Biogen the acquisition is nowhere near as significant as for Sage Therapeutics. Biogen had revenue of $3.38 billion in Q3 2020 and $1.18 billion cash flow from operations.

Sage and Biogen’s depression drug quickly relieved symptoms of depression in a phase 3 trial, but the readout did little to quell concerns about the med’s durability of effect, ...

Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development. The companies are evaluating next steps, if any, for other ...